Janus Henderson Investors US’s Achillion Pharmaceuticals ACHN Stock Holding History

Janus Henderson Investors US’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$18.5M	Sell	4,392,988 -265,857	-6%	-$1.1M	0.02%	617
2016 Q4	$19.2M	Sell	4,658,845 -993,649	-18%	-$5.28M	0.02%	622
2016 Q3	$45.8M	Sell	5,652,494 -59,865	-1%	-$509K	0.04%	435
2016 Q2	$44.6M	Sell	5,712,359 -1,066,645	-16%	-$9.15M	0.04%	445
2016 Q1	$52.3M	Sell	6,779,004 -238,461	-3%	-$1.75M	0.05%	420
2015 Q4	$75.7M	Sell	7,017,465 -317,083	-4%	-$2.88M	0.06%	329
2015 Q3	$50.7M	Buy	7,334,548 +902,220	+14%	+$7.35M	0.05%	413
2015 Q2	$57M	Buy	6,432,328 +1,803,126	+39%	+$17.1M	0.05%	422
2015 Q1	$45.6M	Buy	4,629,202 +1,525,833	+49%	+$19.1M	0.04%	468
2014 Q4	$38M	Sell	3,103,369 -508,610	-14%	-$6.21M	0.03%	498
2014 Q3	$36M	Buy	+3,611,979	New	+$33.5M	0.03%	486
2013 Q4	–	Sell	-2,410,741	Closed	-$7.28M	–	1120
2013 Q3	$7.28M	Buy	2,410,741 +11,878	+0.5%	+$81.4K	0.01%	694
2013 Q2	$19.6M	Buy	+2,398,863	New	+$18.3M	0.02%	503

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Investors US's ACHN Position: Q1 2017 in Review

Janus Henderson Investors US reduced its Achillion Pharmaceuticals (ACHN) stake by 5.7% in Q1 2017, selling an estimated $1.1M and leaving 4,392,988 shares worth $18.5M. The position accounts for 0.02% of the portfolio, ranked #617.

Janus Henderson Investors US first reported a position in ACHN in Q2 2013 and has held it in 13 quarters since. The position peaked at $75.7M in Q4 2015. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

Janus Henderson Investors US held 4,392,988 shares of Achillion Pharmaceuticals worth $18.5M as of Q1 2017.
Janus Henderson Investors US sold 265,857 Achillion Pharmaceuticals shares in Q1 2017, an estimated $1.1M.
Achillion Pharmaceuticals made up 0.02% of Janus Henderson Investors US's portfolio in Q1 2017, its #617 holding.
Janus Henderson Investors US first reported a position in Achillion Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
Janus Henderson Investors US's Achillion Pharmaceuticals position peaked at $75.7M in Q4 2015.
130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.